LivaNova PLC Updates FY22 Earnings Guidance

Trending News 🌥️

LIVANOVA ($NASDAQ:LIVN): LivaNova PLC is a global medical technology company. It designs, develops, manufactures and markets innovative products and services for treating cardiovascular diseases, neurological diseases and chronic pain. The company has updated its FY22 earnings guidance. The company attributed the guidance update to strong operational performance and favorable currency exchange rates.

Earnings

LivaNova PLC has updated its earnings guidance for the fiscal year ending June 30, 2022. The company reported total revenue of 1017.6 million dollars for the second quarter of the fiscal year, a 1.7% decrease compared to the previous year. The company also reported a net loss of 29.1 million dollars.

LivaNova PLC’s total revenue has grown from 934.2 million dollars to 1017.6 million dollars over the last three years. The company attributed the decrease in net income to higher costs associated with new product development and expansion into new markets.

Price History

LivaNova PLC, a global medical technology company, updated its FY22 earnings guidance on Thursday. LivaNova attributed the lower guidance to “continued challenges” in the global healthcare environment. LivaNova’s stock opened at $47.20 on Thursday and closed at $47.80, down 0.8% from its previous close of $48.20.

VI Analysis

LIVANOVA PLC is a medical technology company that develops and markets products for the treatment of cardiovascular diseases. The company’s products include implantable cardioverter defibrillators, pacemakers, and other cardiac rhythm management devices. The company’s fundamentals reflect its long term potential.

However, based on VI’s Risk Rating, LIVANOVA PLC is a high risk investment in terms of financial and business aspects. VI’s app has detected 2 risk warnings in income sheet, balance sheet. Register with us to check it out.

VI Peers

The company’s products include implantable cardioverter defibrillators, pacemakers, percutaneous transluminal coronary angioplasty catheters, stents, and thrombectomy devices. LivaNova PLC operates in Europe, the United States, Asia Pacific, the Middle East, and Africa. The company was formerly known as Sorin Group S.p.A. and changed its name to LivaNova PLC in February 2016. LivaNova PLC was founded in 1956 and is headquartered in London, the United Kingdom. LivaNova PLC’s competitors include MicroPort Scientific Corp, Fukuda Denshi Co Ltd, and PetVivo Holdings Inc.

– MicroPort Scientific Corp ($SEHK:00853)

MicroPort Scientific Corp is a medical device company that develops, manufactures, and markets a broad range of products and solutions for the treatment of cardiovascular diseases. The company has a market cap of 31.83B as of 2022 and a return on equity of -19.11%. MicroPort’s products and solutions are used in a variety of procedures, including coronary angioplasty, stenting, and valve replacement. The company’s products are sold in over 50 countries worldwide.

– Fukuda Denshi Co Ltd ($TSE:6960)

With a market cap of 114.93B as of 2022, Fukuda Denshi Co Ltd is one of the largest companies in Japan. The company produces a wide range of products, including medical equipment, electronic products, and communications equipment. The company has a strong reputation for quality and innovation, and is a major player in the global market. Fukuda Denshi Co Ltd has a return on equity of 9.95%, which is relatively high for a large company. The company’s strong financial performance is due in part to its efficient operations and sound management.

– PetVivo Holdings Inc ($NASDAQ:PETV)

PetVivo Holdings Inc is a pet health and wellness company that focuses on the development and commercialization of pet health products. The company has a market capitalization of $25.78 million and a return on equity of -79.79%. The company’s products include a line of CBD-based pet health products, as well as a line of pet supplements.

Summary

LivaNova PLC issued an update on its FY22 earnings guidance on Wednesday morning. A number of research firms have weighed in on LIVN. BidaskClub raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Thursday, December 3rd. ValuEngine raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Tuesday, December 1st. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. LivaNova last announced its quarterly earnings data on Wednesday, November 4th. The business also recently announced a quarterly dividend, which will be paid on Monday, February 1st.

The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The disclosure for this sale can be found here. A number of institutional investors have recently bought and sold shares of LIVN. LivaNova PLC, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic solutions worldwide. It operates through Cardiac Surgery, Cardiac Rhythm Management , Neuromodulation, and Other segments. The Cardiac Surgery segment offers cardiopulmonary products that are used in open heart surgery and other surgical procedures to correct congenital heart defects, repair valvular heart disease, and bypass blocked or narrowed arteries through cardiopulmonary bypass .